1.
Anurag M, Jaehnig EJ, Krug K, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022;12(11):2586-2605. doi:10.1158/2159-8290.CD-22-0200.
1.
Karaayvaz M, Cristea S, Gillespie SM, et al. Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018;9(1):3588. doi:10.1038/s41467-018-06052-0.
1.
Granit RZ, Masury H, Condiotti R, et al. Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer. Cell Rep. 2018;24(12):3237-3250. doi:10.1016/j.celrep.2018.08.053.
1.
Stover DG, Parsons HA, Ha G, et al. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018;36(6):543-553. doi:10.1200/JCO.2017.76.0033.
1.
Kabraji S, Sole X, Huang Y, et al. AKT1 quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Res. 2017;19(1):88. doi:10.1186/s13058-017-0877-7.
1.
Abdeen SK, Ben-David U, Shweiki A, Maly B, Aqeilan RI. Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer. Cell Death Dis. 2018;9(8):832. doi:10.1038/s41419-018-0896-z.
1.
Tsvetkov P, Adler J, Myers N, Biran A, Reuven N, Shaul Y. Oncogenic addiction to high 26S proteasome level. Cell Death Dis. 2018;9(7):773. doi:10.1038/s41419-018-0806-4.
1.
Suen KM, Lin CC, Seiler C, et al. Phosphorylation of threonine residues on Shc promotes ligand binding and mediates crosstalk between MAPK and Akt pathways in breast cancer cells. Int J Biochem Cell Biol. 2018;94:89-97. doi:10.1016/j.biocel.2017.11.014.
1.
Hebert JD, Myers SA, Naba A, et al. Proteomic Profiling of the ECM of Xenograft Breast Cancer Metastases in Different Organs Reveals Distinct Metastatic Niches. Cancer Res. 2020;80(7):1475-1485. doi:10.1158/0008-5472.CAN-19-2961.
1.
Eismann J, Heng YJ, Waldschmidt JM, et al. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. J Cancer Res Clin Oncol. 2020;146(2):503-514. doi:10.1007/s00432-019-03078-9.